ANDA 84504, held by Watson Labs. Hydralazine Hydrochloride.
As of Nov 16, 2026, ANDA 84504 (Hydralazine Hydrochloride), held by Watson Labs, was first approved by FDA on Nov 23, 1976, with 8 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Nov 23, 1976 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Hydralazine Hydrochloride25MG ยท tablet;oral | Hydralazine Hydrochloride | Discontinued |
| Jul 2, 1996 | Supplement 36Manufacturing | Approved | None posted |
| Aug 7, 1991 | Supplement 34Manufacturing | Approved | None posted |
| Nov 19, 1990 | Supplement 35Manufacturing | Approved | None posted |
| Jun 29, 1990 | Supplement 33Manufacturing | Approved | None posted |
| Apr 24, 1984 | Supplement 18Manufacturing | Approved | None posted |
| Apr 24, 1984 | Supplement 19Manufacturing | Approved | None posted |
| Apr 24, 1984 | Supplement 21Manufacturing | Approved | None posted |
| Apr 24, 1984 | Supplement 22Manufacturing | Approved | None posted |
| Nov 23, 1976 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters